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Background: To update the pattern of cancer mortality in Europe.
Materials and methods: We analysed cancer mortality in 34 European countries during 2000–2004, with an
overview of trends in 1975–2004 using data from the World Health Organization.
Results: From 1990–1994 to 2000–2004, overall cancer mortality in the European Union declined from 185.2 to
168.0/100 000 (world standard, 29%) in men and from 104.8 to 96.9 (28%) in women, with larger falls in middle age.
Total cancer mortality trends were favourable, though to a variable degree, in all major European countries, including
Russia, but not in Romania. The major determinants of these favourable trends were the decline of lung (216%) and
other tobacco-related cancers in men, together with the persistent falls in gastric cancer, and the recent appreciable
falls in colorectal cancer. In women, relevant contributions came from the persistent decline in cervical cancer and the
recent falls in breast cancer mortality, particularly in northern and western Europe. Favourable trends were also
observed for testicular cancer, Hodgkin lymphomas, leukaemias, and other neoplasms amenable to treatment, though
the reductions were still appreciably smaller in eastern Europe.
Conclusion: This updated analysis of cancer mortality in Europe showed a persistent favourable trend over the last
years.
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introduction
Overall cancer mortality rates have peaked in 1988 in the
European Union (EU), and the fall in mortality rates has been
10% up to the end of the last century [1, 2]. Trends were,
however, different in various countries and geographic areas,
with earlier and larger declines in western Europe. Cancer
trends were even less favourable in Russia.
In a previous report, we analysed trends in mortality from all
cancers and major cancer sites in selected European countries
from 1960 to 1999 [1]. To monitor the progress in cancer
mortality in Europe, we present here data for the
quinquennium 2000–2004, together with an overview of trends
over the three last decades. For lung cancer and all neoplasms,
we also used joinpoint regression analysis to identify significant
changes in trends from 1975 to 2004 [3].
materials and methods
We abstracted official death certification numbers for 25 cancer sites in 34
European countries (including the Russian Federation, Ukraine and other
eastern European countries, but excluding a few small countries such as
Andorra, and Liechtenstein, as well as Belgium, whose data were available
only up to 1997, and Cyprus whose data were not available) from the World
Health Organization (WHO) database as available on electronic support
[4]. Besides England and Wales, data were also presented for Scotland and
Northern Ireland. For Denmark, data were available up to 2001; for Belarus,
Italy, Macedonia and Portugal up to 2003. The EU was defined as the 27
member states as since January 2007 (with the exclusion of Belgium and
Cyprus).
During the calendar period considered (1975–2004), three different
revisions of the International Classification of Diseases (ICD) were used
[5–7]. Classification of cancer deaths was recoded, for all calendar periods
and countries, according to the 10th revision of the ICD. To improve
the validity and comparability of data throughout different countries, we
pooled together all intestinal sites (including rectum), all uterine cancers
(cervix and endometrium), all skin neoplasms (melanoma and
nonmelanomatous), all non-Hodgkin lymphomas (NHL) and all
connective and soft tissue sarcomas.
Neoplasms of the brain or nerves are not presented, since it was not
possible to consistently pool together subsequent Revisions of the ICD. We
were also unable to consider long-term trends in pleural cancer mortality
since pleural mesothelioma was unavailable separately in the ICD IX, and the
combination of ICD X codes C45.0 (mesothelioma) and C38.4 (other
malignant neoplasms of the pleura) is influenced by misclassification by lung
cancer, thus introducing spurious trends in men from several countries.
We obtained estimates of the resident population, on the basis of official
censuses, from the same WHO database [4]. From the matrices of certified
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deaths and resident populations, we computed age-specific mortality rates
for each 5-year age group (from 0–4 to 80–84, and ‡85 years) and calendar
period. We computed age-standardised mortality rates per 100 000
population, at all ages and truncated 35–64 years, using the direct method,
on the basis of the world standard population [8]. In a few countries, data
were missing for one or more calendar years. No extrapolation was made
for missing data.
In the interpretation of the data presented, it is important first to
consider problems related to random variation, which are clearly greater in
relation to smaller populations and rarer cancers. Secondly, and more
complex, there are problems of death certification reliability and validity in
various countries [9, 10]. For several common cancer sites, including lung,
stomach, colorectum and breast, death certification is sufficiently reliable to
permit meaningful inference on trends for most European countries, not
only those from western Europe but also major central and eastern
European countries, and chiefly under the age of 65 years. Some under-
recording of cancer deaths was reported for the Russian Federation in the
late 1980s and 1990s, due to a fall in precision of coding of causes of death.
This was, however, mainly restricted to the elderly living in rural areas [11],
and should therefore not have substantially influenced truncated mortality
rates. Greater caution is required for a few other countries (such as Albania
whose rates were apparently low and a few recent national entities for which
no long-term trend was available) and for a few cancer sites, whose
diagnosis and certification may be substantially influenced by the
availability of diagnostic techniques and the accuracy of death certification,
reflecting variable data reliability and different criteria and attitudes
towards death certification. These include, among others, liver, bone, soft
tissue sarcomas, prostate, multiple myeloma (MM) and other lymphoid
neoplasms [9, 10].
To identify significant changes in trends for lung cancer and all cancer
mortality, we carried out joinpoint regression analysis [3, 12].
results and discussion
Table 1 includes the age-standardised mortality rates (at all ages
and truncated 35–64 years) and the observed average annual
number of deaths for major cancer sites in men from 34
European countries and in the EU as a whole, for the period
2000–2004. The corresponding figures in women are given in
Table 2.
Figure 1 shows the world standardised mortality rates (at all
ages and truncated 35–64 years) from 23 cancer sites plus all
neoplasms for men and women in the EU from 1975 to 2004.
Figure 2 includes, for each cancer site, the age-standardised
mortality rates (overall and truncated 35–64 years) for 24
countries selected among the largest ones providing long-term
trends, and for 5-year calendar periods from 1975 to 2004.
Countries are presented in alphabetical order. Different scales
have been used for each neoplasm, in order to assist reading
and interpretation.
Supplemental Figure S2 (available at Annals of Oncology
online) includes corresponding trends for cancers of the liver,
gall-bladder, lung, connective and soft tissue sarcomas, thyroid
and all neoplasms.
Supplemental Table S1 (available at Annals of Oncology
online) gives the major findings from joinpoint regression
analysis for mortality from lung cancer in 34 selected European
countries and in the EU over the period 1975–2004. The
joinpoint analysis for lung cancer mortality is also presented
graphically in 24 major European countries separately for men
and women (Figure 3).
Supplemental Table S2 (available at Annals of Oncology
online) gives the main findings from joinpoint regression
analysis for mortality from all neoplasms in 34 selected
European countries and in the EU over the period 1975–2004.
The joinpoint analysis for total cancer mortality is also
presented graphically in 24 major European countries
separately for men and women (Figure 4).
mouth and pharynx
From 1990–1994 to 2000–2004, mortality from cancer of the
oral cavity and pharynx in the EU as a whole declined by
10%, from 6.6 to 6.0/100 000 at all ages and from 14.4 to 13/
100 000 in middle age (35–64 years). Over the same period,
mortality rates increased in women, to reach 1.2/100 000 at all
ages and 2.1/100 000 at age 35–64 years during 2000–2004.
Tobacco smoking and alcohol drinking (alone and mainly in
combination) are the major risk factors for oral cancer in
Europe, accounting for >80% of cases [13]. The diverging
trends in the two sexes mainly reflect the different patterns in
tobacco smoking, which substantially declined in men over the
last few decades but rose in women from several countries [14,
15]. Trends in alcohol consumption have also been different in
various countries [16], and this is reflected in variable oral
cancer trends across Europe. Countries like France and Italy,
which had the highest alcohol consumption up to the early
1980s, but where alcohol drinking has substantially declined
over the last few decades, showed favourable trends in oral
cancer mortality since the mid-/late 1980s, whereas male trends
were less favourable in most countries from northern Europe,
where alcohol drinking has increased. The most unfavourable
trends and the highest mortality from oral and pharyngeal
cancer, however, were reported in central and eastern Europe,
where mortality rates during 2000–2004 were between 6 and
10/100 000 men at all ages and between 12 and 18/100 000 men
at age 35–64 in countries like the Czech Republic, Croatia,
Poland and Russia. The highest oral cancer mortality was in
Hungary, where mortality rates in the early 2000s were 21.1/
100 000 at all ages and 55.3/100 000 at age 35–64, and Slovakia,
with an overall mortality rate of 16.9/100 000. Besides the high
alcohol and tobacco consumption, this may point to a specific
role of fruit-based alcoholic beverages, frequently drunk in
those areas [17–19].
oesophagus
This is another neoplasm strongly related to tobacco and
alcohol (and their interaction), and its trends across Europe are
at least partly similar to those of oral cancer [17, 20, 21].
Oesophageal cancer mortality has been moderately decreasing
in EU men from 1990–1994 to 2000–2004, from 5.7 to 5.4/
100 000 at all ages and mostly in middle age (from 10 to 9/
100 000). In women, over the same period, mortality rates have
been stable around 1.1/100 000 at all ages and have increased
from 1.4 to 1.5/100 000 in middle age. As for oral cancer, over
the last decade, mortality rates were substantially downwards in
France, Italy and Spain, following the decline in alcohol
consumption in these countries, besides the fall of tobacco
smoking in men [21]. Conversely, oesophageal cancer mortality
has increased in most northern, central and eastern Europe.
Appreciable rises were also observed in Denmark, Scotland and
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Table 1. Overall age-adjusted (world population) mortality rates (first row) and average annual number of deaths (second row) from selected cancers per 100 000 men in 34 European countries plus the EU
during 2000–2004 (unless otherwise specified)
Countries Mouth or
pharynx
Esophagus Stomach Intestines Liver Gall-
bladder
Pancreas Larynx Lung Bone Soft
tissue
Skin
total
Prostate Testis Bladder Kidney Thyroid HL NHL MM Leukaemias All
neoplasms
Albania 2.43 1.49 14.78 3.57 – 0.21 4.32 3.37 30.87 1.75 0.42 1.47 9.19 0.28 – 2.61 0.28 0.7 0.87 0.26 3.78 114.25
37 22 227 55 – 3 66 51 464 27 6 21 137 4 – 40 4 11 13 4 57 1733
Austria 6.36 3.88 9.31 20.09 4.4 2.05 9.08 2.46 35.41 0.49 0.85 2.85 17.63 0.31 5.15 4.36 0.51 0.33 4.23 2.01 5.71 156.76
362 232 606 1308 397 136 580 146 2319 23 48 174 1170 15 341 280 32 19 269 134 352 9959
Belarus (2000–2003) 9.72 5.27 29.26 18.26 – – 7.02 8.48 55.23 – – 1.52 10.63 – 7.5 – – – 2.07 0.97 5.59 204.43
554 305 1754 1099 – – 208 494 3279 – – 46 656 – 229 – – – 60 30 322 12 067
Bulgaria 4.48 1.99 13.9 17.67 – 0.89 7.38 5.52 39.41 1.06 0.32 1.74 7.4 0.71 4.63 2.75 0.37 0.9 1.73 0.48 3.85 140.28
265 128 965 1245 – 63 491 334 2496 59 16 111 724 35 331 176 24 48 101 31 219 9201
Croatia 10.43 5.35 17.39 25.78 – 2.17 8.54 6.76 62.11 1.46 0.61 3.5 14.89 0.51 6.43 4.84 0.38 0.45 3.75 2.12 5.53 212.54
320 219 598 1117 – 77 286 224 2099 43 18 109 525 13 225 164 13 13 120 73 176 7145
Czech Republic 7.19 4.66 11.25 35.77 2.85 3.75 11.12 3.53 58.02 0.9 0.66 3.58 18.63 0.66 7.11 10.5 0.4 0.67 3.63 2.31 6.71 215.93
515 346 840 2687 297 283 829 260 4330 59 45 253 1409 40 546 789 30 46 265 175 488 16 029
Denmark (2000–2001) 4.99 6.67 5.3 21.91 1.5 0.87 7.98 1.94 43.94 0.51 0.74 3.42 21.92 0.55 7.95 5.1 0.32 0.26 4.59 2.75 5.75 175.98
204 285 236 1027 62 42 354 87 1977 16 28 147 1105 18 392 228 14 11 204 125 240 8006
Finland 2.35 2.96 7.19 12.94 2.79 1.26 8.86 0.76 31.85 0.43 0.75 2.53 18.32 0.16 3.64 4.85 0.43 0.33 5.38 2.54 4.32 130.85
94 122 302 536 164 52 366 40 1376 14 30 101 776 5 153 199 18 12 223 111 165 5444
France 8.57 7.19 5.87 17.48 6.72 0.92 7.58 3.34 44.05 0.87 0.76 2.06 14.43 0.29 5.91 3.86 0.28 0.39 4.34 2.38 5.46 178.16
3691 3358 3111 9623 3975 530 3822 1526 20 894 357 328 1003 9204 101 3326 1987 144 166 2244 1340 2816 90 480
Germany 5.67 4.92 8.69 19.03 2.92 1.62 8.2 1.97 39.17 0.4 0.7 2.06 13.78 0.34 4.56 4.3 0.39 0.3 3.7 2.29 5.02 151.5
3654 3383 6529 14 467 3039 1334 6035 1352 28 789 222 444 1443 11 265 187 3638 3166 285 197 2689 1759 3550 112 020
Greece 1.89 1.54 8.16 9.78 1.61 0.97 6.7 3 48.5 1.72 0.38 1.61 11.62 0.37 6.92 2.86 0.25 1.43 1.52 1.54 6.36 147.47
172 150 845 1056 217 105 677 308 4831 159 33 152 1346 26 785 297 27 131 147 159 648 15 074
Hungary 21.12 8.23 15.6 34.56 5.43 3.27 10.86 7.5 78.86 0.98 0.84 3.7 15.63 0.88 7.59 6.11 3.99 0.49 0.61 1.87 7.09 255.19
1430 572 1217 2706 408 260 814 522 5766 65 53 271 1329 51 606 456 36 40 293 145 519 18 993
Iceland 2.12 3.9 7.99 15.87 2.07 1.23a 7.31 0.77b 26.71 0.92b 0.99b 2.33 21.13 0.5a 4.03 0.9 6.9 1.06b 2.85 1.27 3.28 125.15
4 8 16 34 3 2 14 2 54 2 2 5 48 1 9 2 13 2 6 3 7 261
Ireland 3.55 7.67 7.54 20.03 0.8 0.61 7.17 1.87 36.41 0.63 1.11 2.63 18.52 0.28 3.84 4.62 0.34 0.46 5.04 2.96 5.74 156
88 199 198 530 30 16 187 48 954 15 27 67 531 6 108 116 9 12 127 79 151 4113
Italy (2000–2003) 4.38 2.94 11.39 16.9 6.17 2.16 7.6 3.18 46.35 0.61 0.79 2.25 11.55 0.25 6.77 3.73 0.39 0.46 4.65 2.28 5.92 168.51
2112 1529 6402 9563 3370 1244 4095 1716 25 725 250 352 1125 7225 92 4075 2021 207 208 2416 1311 2990 93 044
Latvia 8.11 5.49 20.69 19.31 – 1.12 10.96 5.6 56.68 1.46 0.85 2.77 18.1 0.8 8.09 7.35 0.54 0.61 3.66 1.47 5.72 203.4
121 84 318 305 – 18 169 86 892 21 12 41 284 11 127 115 8 8 54 23 83 3134
Lithuania 10.67 6.42 21.56 19.94 1.42 1.42 10.06 5.54 54.81 0.93 0.73 2.38 19.59 0.54 7.55 7.63 0.46 0.83 2.86 1.95 6.77 204.37
213 134 471 440 36 30 217 116 1203 19 15 50 435 10 167 164 10 16 60 42 139 4414
Luxembourg 7.74 5.09 7.2 19.33 0.28 0.73 8.79 2.35 45.01 0.9 0.89 2.85 13.51 0.32c 5.31 3.57 0.6 0.44 3.52 1.94 5.16 157.56
24 17 23 66 1 5 30 7 150 2 3 9 46 1 18 12 2 1 15 6 17 521
Macedonia (2000–2003) 3.08 1.85 19.19 14.77 – 1.08 6.2 5.96 41.99 1.84 0.26 3.93 8.92 0.69 6.67 2.23 0.31 1.25 1.79 0.92 4.15 153.72
38 23 239 187 – 13 78 74 521 22 3 46 111 8 83 27 3 15 22 11 49 1897
Malta 2.86 2.41 7.95 15.63 0.78 0.85 8.43 1.62 37.49 0.82b 0.58b 1.55 10.39 0.52 6.27 3.56 0.51 0.43 4.64 1.73 4.97 134.46
8 7 24 46 3 3 24 5 109 2 2 5 34 2 20 11 2 2 13 5 13 398
Moldova Republic 11.21 3.06 16.67 18.46 – 0.68 7.55 6.35 34.53 1.72 0.46 2 5.25 0.51 5.61 2.74 0.31 1.32 2.7 0.64 4.09 149.21
205 56 308 339 – 13 139 114 627 32 9 37 95 9 102 50 6 24 49 11 71 2721
The Netherlands 3 7.29 7.69 20.55 1.07 0.89 7.25 1.57 49.9 0.58 0.86 3.03 18.06 0.31 6.1 4.31 0.24 0.41 5.07 2.79 5.18 171.79
354 892 963 2577 182 108 901 190 6342 55 92 349 2331 28 789 533 30 45 618 355 607 21 402
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Table 1. (Continued)
Countries Mouth or
pharynx
Esophagus Stomach Intestines Liver Gall-
bladder
Pancreas Larynx Lung Bone Soft
tissue
Skin
total
Prostate Testis Bladder Kidney Thyroid HL NHL MM Leukaemias All
neoplasms
Norway 2.8 3.09 6.7 20.56 0.93 1.06 7.44 0.95 31.1 0.44 0.63 4.31 23.56 0.41 5.65 4.12 0.29 0.28 4.69 3.03 4.41 143.76
96 113 271 832 52 41 287 36 1175 12 21 155 1068 12 252 159 11 9 175 124 164 5691
Poland 6.02 4.95 15.35 20.44 4.2 1.93 8.07 6.25 67.87 1.16 0.48 3.09 13.64 0.52 8.54 6.16 0.33 0.87 3.28 1.89 5.68 209.77
1412 1166 3757 5022 1025 474 1949 1490 16 401 269 107 721 3394 113 2118 1480 81 202 784 466 1320 50 688
Portugal (2000–2003) 6.83 5.48 17.44 17.24 2.75 1.28 5.79 4.88 28.8 0.92 0.61 1.69 15.93b 0.31 4.83 2.26 0.31 0.47 3.76 1.99 4.9 148.79
497 434 1561 1837 231 122 508 381 2434 66 44 144 1715 20 480 201 27 33 312 184 400 13 341
Romania 10.04 3.03 16.75 14.82 1.55 1.27 8.26 5.62 46.94 2.27 0.86 2.78 9.62 0.58 5.93 1.3 0.33 0.74 2.59 0.71 4.59 165.75
1416 445 2646 2362 342 199 1281 827 7024 330 119 406 1593 77 959 246 50 103 366 137 634 25 100
Russian Federation 8.86 6.58 28.76 19.08 5.69 – 4.28 6.49 57.17 – – 1.5 8.84 – 7.11 – – – 2.13 0.82 5.1 195.03
7240 5376 23 900 15 826 4684 – 6499 5363 47 435 – – 1238 7313 – 5873 – – – 1704 680 3951 160 450
Slovakia 16.86 7.24 14.45 33.65 – 2.7 9.78 5.86 53.72 0.82 0.64 2.91 14.45 0.64 5.77 6.73 0.4 0.7 3.14 2.3 5.95 212.75
538 228 478 1104 – 90 316 187 1724 25 19 94 490 20 195 217 101 22 14 77 187 6888
Slovenia 8.35 4.91 15.29 24.93 – 2.34 8.17 3.88 50.61 0.56 0.64 3.76 18.45 0.47 6.03 4.9 3.81 0.4 0.38 2.17 5.29 192.09
118 71 226 368 – 35 120 56 747 7 7 52 272 6 90 72 53 5 6 33 72 2799
Spain 6.05 4.89 10.06 19.74 5.22 1.18 6.62 5.1 46.6 0.56 0.72 1.91 13.65 0.16 8.92 3.04 3.67 0.45 0.27 2.14 5 171.44
1817 1557 3646 7411 2906 472 2290 1668 16 183 154 213 648 5619 43 3468 1074 95 136 1259 816 1664 612 43
Sweden 2.19 3.17 5.41 15.27 0.77 1.99 7.6 0.54 20.89 0.43 0.93 3.04 23.28 0.17 4.33 4.42 0.27 0.3 4.45 2.63 4.58 125.78
174 269 488 1408 64 182 667 48 1795 24 68 251 2497 10 435 393 25 22 396 253 391 115 50
Switzerland 4.64 4.9 5.25 13.07 5.99 – 6.96 1.41 32.39 – – 2.3 17.49 – 4.32 – – – 4.45 2.27 4.49 136.89
259 295 339 853 364 – 441 83 1988 – – 138 1303 – 299 – – – 278 150 270 8728
Ukraine 10.55 4.85 22.58 18.15 – – – 6.4 47.17 – – – 8.24 – – – – – – – 5.5 193.84
3130 1474 7096 5829 – – – 1940 14 755 – – – 2746 – – – – – – – 1530 59 386
UK: England and Wales 2.58 8.53 6.71 17.22 1.37 0.35 6.33 1.26 35.79 0.46 0.76 2.42 15.43 0.21 5.35 3.88 0.2 0.39 4.77 2.42 4.68 147.32
1068 3981 3395 8469 849 179 2982 576 17 420 142 298 1059 8910 66 2899 1760 96 146 2151 1207 2106 71 854
UK: Northern Ireland 2.67 7.8 7.78 20.32 1.17 0.51 6.43 1.32 38.07 0.44 0.68 2.22 14.7 0.37 3.98 4.38 0.24 0.44 5.06 2.35 4.35 150.64
32 96 101 260 20 6 82 16 490 4 6 27 216 3 56 53 3 5 62 32 52 1939
UK: Scotland 4.19 10.93 8.15 21.48 2.07 0.52 6.71 2.1 49.88 0.54 0.82 2.63 15.49 0.3 5.61 4.4 0.26 0.37 4.59 2.38 4.46 174.78
163 475 369 973 126 23 290 88 2231 15 29 107 783 10 272 188 10 13 196 111 184 7792
EU 5.97 5.37 9.87 18.82 3.76 1.42 7.69 3.28 44.00 0.74 0.72 2.35 14.31 0.35 6.12 4.2 0.33 0.49 3.99 2.21 5.3 168.03
20 599 20 187 39 900 77 888 17 169 6031 30 190 12 114 175 195 2384 2433 8842 64 991 997 26 439 16 421 1287 1652 15 440 9099 20 070 667 910
a2000–2002.
b2000–2003.
c2000–2001.
EU, European Union; HL, Hodgkin lymphoma; NHL, non-Hodgkin lymphoma; MM, multiple myeloma.
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the Baltic countries. During 2000–2004, the highest mortality
rates in men were in Scotland (10.9/100 000), England and
Wales and Hungary, though with some hint of levelling off over
more recent calendar years. The lowest ones (<3/100 000) were
in Greece, Bulgaria, Italy and Finland. In women, the highest
oesophageal cancer mortality rates (4/100 000) were in
Scotland, followed by England and Wales and Ireland. Part
of the rise in northern Europe is due to an increase in
oesophageal adenocarcinoma, which is now higher than
squamous cell carcinoma in countries like Denmark and
Scotland [21–23]. Oesophageal adenocarcinoma is related to
tobacco (but not alcohol), overweight and gastro-oesophageal
reflux [24, 25]. Therefore, at least part of the rise in oesophageal
cancer mortality in northern Europe can be attributed to
increased prevalence of overweight and obesity. Squamous cell
carcinoma remained the prevalent histological type in southern
Europe [21].
stomach
From 1990–1994 to 2000–2004, gastric cancer mortality in the
EU declined from 14.1 to 9.9/100 000 men and from 6.4 to 4.5/
100 000 women (i.e. by 30% in both sexes), with similar
declines in middle age population for both sexes. Thus, in
relative terms, the steady fall in gastric cancer mortality
persisted over most recent years [26]. During 2000–2004, the
highest mortality rates were in Belarus (29.3/100 000 men,
11.5/100 000 women) and Russia (28.8/100 000 men, 11.8/
100 000 women), followed by the Baltic countries (20–21/
100 000 men, 9/100 000 women) and Portugal (17.4/100 000
men, 8/100 000 women). The lowest ones were in Switzerland,
France, the Nordic countries and England and Wales (5–6/
100 000 men, 2–3/100 000 women). Falls in gastric cancer
mortality were observed both in high-mortality areas (not only
Russia and most other eastern and central European countries,
but also Portugal and Italy), and in low-mortality ones (not
only most northern Europe, but also France and Greece). Thus,
the declines in gastric cancer mortality throughout Europe are
likely to continue in the near future. They are mainly attributed
not only to improved diet, diet variety and food conservation
[27, 28], but also to a declined prevalence of Helicobacter pylori
infection in more recent generations [29]. A role of improved
diagnosis and treatment is also possible, although difficult to
quantify on national mortality rates [23, 30].
intestines, chiefly colon and rectum
Mortality from colorectal cancer in the EU has been declining
from 13.4 to 11.5/100 000 from 1980–1984 to 2000–2004 in
women and from 20.1 to 18.8/100 000 from 1990–1994 to
2000–2004 in men. These falls were somewhat larger in middle
age. The favourable trends in colorectal cancer mortality were
observed in most western and northern Europe, whereas trends
were less favourable in southern (particularly Spain) and most
central and eastern European countries, which had lower
mortality rates in the past [31]. This likely reflects more
uniform dietary and lifestyle habits across Europe over more
recent calendar years. There is, however, a persisting substantial
excess in colorectal cancer mortality in Hungary and the
Czech Republic, with mortality rates during 2000–2004 about
35/100 000 men and about 18/100 000 women. Most other
European countries have mortality rates between 17 and 20/
100 000 men and between 10 and 13/100 000 women. The
lowest mortality rates (10–13/100 000 men, 7–10/100 000
women) are in Greece, Finland, Switzerland, Romania and
France. Some of the recent falls in mortality, which have been
observed in North America [32, 33] and Japan [34, 35], too, are
likely due to improved detection (through screening and early
diagnosis) and treatment of the disease [23, 36].
liver
From 1980–1984 to 2000–2004, mortality from primary liver
cancer moderately declined in both sexes in the EU, from 4.3 to
3.8/100 000 men and from 1.5 to 1.0/100 000 women. Death
certification data from liver cancer, however, are extremely
difficult to interpret since liver is one of the most common sites
of secondaries and the distinction between primary and
metastatic liver cancer is variable across countries, calendar
periods and subsequent revisions of the ICD [37]. These major
limitations notwithstanding, primary liver cancer mortality
rates, after earlier rises, have been declining over more recent
years in France and Italy, which had some of the highest
mortality rates. This is mainly due to the fall in alcohol
consumption in those countries since the early 1980s [18],
together with the declined prevalence of hepatitis B and C
infection over recent years [38]. In contrast, liver cancer
mortality rates tended to increase in several central and
northern European countries, reflecting the recent rise in
alcohol drinking in these areas of the continent [18]. Still,
during 2000–2004, the highest mortality rates were in France,
Italy and Switzerland (6–6.7/100 000 men) and the lowest ones
in the Nordic countries and the UK. In women, the highest
mortality rates (2–2.7/100 000) were in Poland, Russia and
Hungary. Some of the recent trends in men may have been
favourably influenced by the decline in tobacco smoking, since
this is another tobacco-related site [39].
gall-bladder and bile ducts
Mortality from gall-bladder and bile duct cancers is higher in
women than in men, and from 1980–1984 to 2000–2004, their
mortality rates declined from 2.4 to 1.9/100 000 in EU women
and from 1.7 to 1.4/100 000 in EU men. The highest mortality
rates during 2000–2004 were in central Europe (the Czech
Republic, Hungary, Slovakia and Poland, between 4 and 5/
100 000 women). The major cause of gall-bladder cancer is the
presence of gallstones [40, 41], which in turn are related to
obesity, multiple pregnancies and other hormonal factors.
Cholecystectomy in subjects with gallstones is an obvious mean
to prevent gall-bladder cancer, and the increased rate of
cholecystectomy in Europe is the major determinant of the falls
in gall-bladder cancer mortality. Fewer data are available on
biliary tract cancers, which are rarer than gall-bladder cancer,
and whose incidence has fallen in Denmark over recent years
too [41, 42].
pancreas
Mortality from pancreatic cancer, after earlier rises, has been
approximately stable from 1980–1984 to 2000–2004 in EU men
(7.6/100 000), while it has steadily risen in women (from 4.8
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Table 2. Overall age-adjusted (world population) mortality rates (first row) and average annual number of deaths (second row) from selected cancers per 100 000 women in 34 European countries plus the
EU in 2000–2004 (unless otherwise specified)
Countries Mouth or
pharynx
Esophagus Stomach Intestines Liver Gall-
bladder
Pancreas Larynx Lung Bone Soft
tissue
Skin.
total
Breast Uterus Ovary Bladder Kidney Thyroid HL NHL MM Leukaemias All
neoplasms
Albania 1.15 0.62 7.07 3.02 – 0.23 2.27 0.79 7.54 1.12 0.34 0.87 7.65 3.36 – – 1.2 0.24 0.31 0.44 0.28 2.54 60.04
20 11 121 51 – 4 38 13 127 18 6 15 122 54 – – 20 4 5 7 3 40 996
Austria 1.4 0.67 5.17 11.44 0.95 2.31 6.71 0.28 11.83 0.25 0.63 1.73 18.57 5.36 6.18 1.45 2.18 0.56 0.22 2.69 1.52 3.39 97.84
111 60 553 1239 141 249 700 20 1002 16 48 149 1593 487 424 175 227 59 17 267 161 321 9343
Belarus (2000–2003) 0.73 0.36 11.53 10.89 1.34 – 3.23 0.12 3.71 – – 1.11 14.58 8.28 5.95 0.73 – – – 1.01 0.98 3.36 86.6
69 40 1190 1144 69 – 170 11 383 – – 48 1256 747 259 44 – – – 47 44 287 8147
Bulgaria 0.81 0.48 6.62 10.61 4.49 1.07 3.91 0.31 6.39 0.62 0.15 1.04 14.74 10.17 – 1.04 1.01 0.41 0.46 0.91 0.38 2.55 81.23
63 45 616 984 363 101 352 24 520 42 10 88 1119 717 – 101 81 35 26 67 30 171 6549
Croatia 1.07 0.64 6.98 12.77 – 2.76 4.71 0.4 10.72 0.79 0.36 2.19 18.2 6.27 6.45 1.35 1.87 0.41 0.29 2.26 1.28 3.16 101.7
47 33 373 685 – 151 248 19 494 32 13 99 825 297 284 83 93 21 10 104 68 148 4966
Czech Republic 1.09 0.62 5.57 17.94 1.01 4.92 7.22 0.2 12.86 0.54 0.51 2.08 19.02 9.06 7.87 1.73 4.49 0.59 0.52 2.39 1.62 3.9 120.95
109 66 633 2093 157 578 816 22 1306 48 45 213 1947 902 769 207 498 68 44 257 188 401 12 906
Denmark (2000–2001) 1.68 2.15 2.55 17.29 0.42 0.94 7.03 0.45 28.1 0.21 0.64 2.6 25.91 5.96 9.14 2.85 2.92 0.34 0.24 3.22 1.86 3.31 140.99
91 120 156 1120 21 60 416 23 1460 3 31 133 1331 318 456 189 170 20 13 182 114 192 7920
Finland 0.88 0.92 4 8.94 0.93 1.89 6.67 0.1 8.23 0.24 0.62 1.37 15.57 3.59 5.6 0.92 2.51 0.37 0.25 3.62 1.93 2.78 85.07
56 66 262 594 89 128 427 5 485 10 29 83 816 219 304 70 161 27 12 233 130 157 5138
France 1.27 1.01 2.23 10.09 0.95 0.98 4.43 0.27 8.24 0.41 0.56 1.3 18.29 4.43 5.15 1.07 1.55 0.32 0.23 2.61 1.58 3.22 85.99
734 697 1918 8703 827 863 3518 146 4858 224 314 893 11 080 2900 3261 1051 1148 261 123 2036 1333 2392 61 024
Germany 1.18 1 4.71 12.01 0.76 2.2 5.56 0.2 11.12 0.29 0.53 1.25 18.81 4.47 5.9 1.35 1.91 0.42 0.21 2.41 1.56 3.15 94.48
1031 1003 5728 15 644 1194 2751 6579 180 10 383 211 475 1263 17 573 4405 5899 2005 2210 507 182 2696 1861 3319 102 085
Greece 0.71 0.34 4.1 7.11 0.32 0.94 4.09 0.23 7.61 1.04 0.23 1.18 15.64 3.32 3.96a 1.21 1.15 0.28 0.9 1.03 1.01 3.74 79.68
81 45 518 931 60 124 530 26 892 194 23 131 1714 369 393 172 150 38 96 121 135 442 9489
Hungary 3.25 1.16 6.73 18.2 1.98 4.39 6.52 0.72 22.13 0.48 0.53 2.18 21.64 9.32 6.21 1.67 2.6 0.54 0.42 2.23 1.17 4.45 131.53
288 117 867 2353 240 586 810 63 2259 47 49 249 2290 942 653 224 322 66 37 253 144 479 14 775
Iceland 1.58 1.14 3.33 10.58 0.35 1.05b 5.56 0.67c 25.79 0.51c 0.45b 1.56 15.78 4.2 7.78 1.72 4.02 0.7 0.26 2.03 3.13 2.25 106.64
4 3 10 26 2 4 14 1 55 1 1 4 34 9 18 5 9 2 1 5 8 5 245
Ireland 1.15 3.24 3.74 11.51 0.31 0.93 5.44 0.25 17.94 0.42 0.83 1.8 22.77 4.82 8.55 1.35 1.71 0.4 0.29 3.66 1.78 3.26 113
36 117 130 404 14 32 190 9 577 11 23 58 648 138 223 51 54 12 8 118 66 107 3612
Italy (2000–2003) 1.06 0.6 5.64 10.53 1.78 2.44 5.33 0.22 8.87 0.34 0.61 1.38 18.08 3.96 4.69 1.12 1.45 0.46 0.32 3.07 1.68 3.61 94.78
728 473 4670 8493 1471 1989 4310 159 6290 177 332 911 11 412 2701 769 1056 1106 360 170 2269 1110 2471 69 665
Latvia 0.95 0.46 9.01 12.29 – 1.12 5.39 0.15 6.16 0.7 0.37 2.34 18.05 10.37 7.35 1.3 2.79 0.68 0.4 1.69 1.18 3.58 98.22
24 14 260 373 – 34 160 4 175 15 10 60 419 250 178 44 82 20 8 44 33 89 2621
Lithuania 1 0.52 9.05 11.39 0.43 1.77 4.81 0.15 5.55 0.47 0.6 2.09 18.05 12.71 8.35 1.21 3.18 0.61 0.51 1.61 1.62 4.27 101.74
33 19 339 447 19 71 190 5 213 13 17 68 567 391 273 53 115 23 14 60 61 137 3522
Luxembourg 1.49 1.12 2.62 10.53 0.34 0.6 5.8 0.35 11.02 0.46 0.57 2.2 18.61 3.6 6.43 1.12 1.75 0.38 0.21 2.74 1.9 3.51 90.77
5 6 14 57 2 4 31 2 45 1 2 9 79 16 27 7 10 2 1 13 9 18 423
Macedonia (2000–2003) 0.85 0.49 8.28 9.05 – 2.18 3.16 0.49 6.58 1.31 0.33 2.33 17.49 8.97 – 0.96 0.62 0.31 0.38 0.76 0.66 2.8 87.82
12 7 123 132 – 32 48 7 92 17 4 31 236 122 – 15 8 5 5 11 10 35 1223
Malta 0.78 0.41 4.11 11.29 0.56 0.9 6.33 0.43 5.57 0.4 0.42c 0.99c 21.24 5.15 7.64 1.03 1.62 0.72 0.61 2.18 1.48 3.13 91.03
3 2 17 44 2 3 25 1 19 1 2 4 74 17 25 6 5 3 2 8 6 10 330
Moldova Republic 1.08 0.43 6.91 10.7 – 0.84 3.61 0.2 6.18 0.88 0.37 1.3 17.04 10.89 3.88 0.81 1.27 0.5 0.65 1.79 0.45 3.09 85.67
27 12 182 285 – 23 97 5 158 20 8 35 418 270 94 23 31 13 15 42 11 64 2140
The Netherlands 1.31 2.19 3.63 14.64 0.32 1.06 5.61 0.3 18.32 0.34 0.68 1.82 23.06 3.93 6.14 1.73 2.18 0.34 0.21 3.28 1.73 3.22 112.69
191 365 642 2643 67 189 960 44 2540 40 88 261 3407 621 946 330 363 61 30 531 313 520 17 919
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Table 2. (Continued)
Countries Mouth or
pharynx
Esophagus Stomach Intestines Liver Gall-
bladder
Pancreas Larynx Lung Bone Soft
tissue
Skin.
total
Breast Uterus Ovary Bladder Kidney Thyroid HL NHL MM Leukaemias All
neoplasms
Norway 1.03 0.9 3.28 15.38 0.39 1.06 5.97 0.15 16.59 0.3 0.46 2.54 16.72 5.27 7.35 1.85 2.16 0.41 0.13 3.08 1.9 2.93 103.44
51 46 185 868 28 58 323 8 691 9 20 110 730 239 318 122 113 24 7 152 117 141 5061
Poland 1.12 0.75 5.57 12.36 2.71 3.87 5.12 0.53 13.39 0.65 0.33 2.15 15.08 9.73 7.01 1.28 2.54 0.51 0.51 1.85 1.42 3.41 111.04
373 274 2108 4749 1030 1478 1898 165 4424 194 90 762 4838 3091 2198 518 903 200 149 628 529 1126 38 443
Portugal (2000–2003) 0.83 0.73 7.96 11.37 0.67 1.25 3.32 0.2 5.01 0.55 0.48 1.19 15.56 5.89 3.21 1.09 0.83 0.36 0.29 2.41 1.52 3.06 80.86
93 99 988 1468 75 165 432 24 549 50 43 140 1571 604 176 178 101 44 26 270 189 315 9265
Romania 1.26 0.42 6.27 9.36 0.59 1.24 4.19 0.29 8 1.23 0.57 1.79 16.51 14.65 4.15 1.16 1.3 0.46 0.41 1.41 0.71 3.04 93.28
231 87 1341 2003 168 267 888 55 1564 212 97 354 3010 2484 749 268 246 95 64 246 137 483 17 666
Russian Federation 1.08 0.99 11.75 12.78 2.52 – 4.28 0.18 5.80 – – 1.2 17.34 9.45 5.86 0.81 – – – 1.13 0.72 3.33 96.19
1552 1678 17 694 19 634 3631 – 6494 252 8582 – – 1516 22 076 12 354 7467 1407 – – – 1415 959 3864 132 643
Slovakia 1.2 0.62 5.8 15.77 – 4.16 5.04 0.25 7.7 0.49 0.39 1.85 17.4 9.45 6.18 1.11 2.87 0.47 0.47 1.87 1.66 3.64 102.64
53 28 299 815 – 215 254 10 360 20 17 83 773 418 263 61 138 26 19 87 82 158 4831
Slovenia 1.08 0.67 6.11 12.42 – 2.42 5.14 0.3 11.39 0.38 0.31 2.23 19.15 6.9 6.09 1.25 1.78 0.42 0.26 2.35 1.79 2.79 100.83
20 16 147 309 – 62 122 6 229 7 7 47 383 141 118 34 42 11 5 55 43 60 2213
Spain 0.89 0.5 4.44 11.06 1.57 1.56 3.95 0.17 5.28 0.35 0.54 1.19 14.52 4.18 4.25 1.19 1.12 0.34 0.28 2.39 1.54 3 78.85
387 238 2287 5790 1200 868 2006 67 2134 115 192 553 5822 1793 1707 734 550 176 104 1138 817 1303 36 673
Sweden 0.92 0.99 3.03 11.39 0.31 3.06 6.74 0.12 14.4 0.24 0.77 1.99 16.01 4.54 7.04 1.41 2.57 0.37 0.19 2.95 1.76 3 98.72
98 116 361 1412 32 359 775 12 1350 20 66 189 1514 473 652 198 300 51 17 355 228 316 10 731
Switzerland 1.25 1.06 2.35 8.22 1.79 – 4.97 0.19 11.06 – – 1.46 17.91 3.41 5.31 1.42 2.5 – 0.67 2.75 1.53 2.86 84.99
90 96 223 796 160 – 462 14 738 – – 105 1356 293 427 151 173 – 38 245 147 230 7153
Ukraine 0.88 0.39 8.88 10.78 – – – 0.11 5.17 – – – 17.9 10.21 – – – – – – – 3.45 95.13
444 229 4531 5784 – – – 55 2677 – – – 7871 4579 – – – – – – – 1326 43 961
UK: England and Wales 1.05 3.12 2.79 10.61 0.34 0.51 4.74 0.23 18.76 0.32 0.63 1.59 20.6 4.34 7.49 1.81 1.85 0.27 0.25 2.85 1.63 2.87 107.14
600 2268 2078 7626 260 345 3174 143 11 326 112 292 897 11 321 2402 4013 1496 1108 183 109 1924 1122 1697 66 475
UK: Northern Ireland 1.12 2.84 3.68 12.69 0.42 0.88 4.76 0.3 19.34 0.23 0.65 1.33 19.88 4.32 7.73 1.43 1.74 0.42 0.24 3.5 1.43 2.22 108.36
18 56 71 241 9 16 89 5 315 4 8 25 297 69 120 30 32 6 3 61 29 39 1843
UK: Scotland 1.36 4.04 2.87 13.06 0.5 0.65 4.95 0.44 28.86 0.34 0.65 1.44 20.77 4.79 7.43 2.17 2.25 0.3 0.14 3.44 1.69 2.9 123.09
66 285 202 911 38 42 319 23 1712 12 30 84 1117 255 412 169 136 20 8 213 117 161 7508
EU 1.15 1.14 4.52 11.53 1.03 1.89 5.07 0.26 11.37 0.43 0.55 1.49 18.09 5.7 5.89 1.34 1.83 0.4 0.31 2.5 1.52 3.25 96.91
5551 6679 27 363 71 942 6819 11 607 30 098 1246 57 166 1729 2346 7741 86 974 27 235 24 086 9455 10 298 2379 1287 14 191 9310 16 944 524 781
a1995–1999.
b2000–2002.
c2000–2003.
EU, European Union; HL, Hodgkin lymphoma; NHL, non-Hodgkin lymphoma; MM, multiple myeloma.
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Figure 1. Trends in age-standardised (world population) death certification rates per 100 000 from 23 cancers sites plus all neoplasms in the European
Union, 1975–2004. , men, all ages; , women, all ages; men, 35–64 years; , women, 35–64 years.
original article Annals of Oncology
1330 | La Vecchia et al. Volume 21 | No. 6 | June 2010
Figure 2. Trends in age-standardised (world population) death certification rates per 100 000, for each cancer site and all neoplasms, in 24 selected
European countries, 1975–2004. , men, all ages; , women, all ages; men, 35–64 years; , women, 35–64 years.
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Figure 3. Joinpoint analysis for lung cancer mortality in men and women from 24 selected European countries, 1975–2004. , all ages; , 35–64 years.
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Figure 3. (Continued)
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Figure 4. Joinpoint analysis for all neoplasm mortality in men and women from 24 selected European countries, 1975–2004. , all ages; , 35–64 years.
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to 5.1/100 000). As for other tobacco-related neoplasms, this
reflects the different spread of tobacco over the last decades in
European men and women [43]. The risk of pancreatic cancer
is, in fact, about twofold higher in smokers than in nonsmokers
[44]. The geographic distribution of pancreatic cancer partly
reflects the different prevalence of tobacco use among men and
women in different areas of the continent, since the highest
mortality rates in men (>10/100 000) were in the Czech
Republic, the Baltic countries and Hungary, while in women the
highest mortality rates were in the Czech Republic, Denmark
and Sweden (6–7/100 000). Likewise, recent male trends were
favourable in the UK, The Netherlands, the Czech Republic and
Nordic countries, but unfavourable in most central, eastern and
southern Europe. Pancreatic cancer has also been related to
diabetes and selected nutritional and dietary factors, including
obesity, high intake of (saturated) fats and low intake of
vegetables and fruits [45, 46], but the potential impact of these
factors on national mortality remains unquantified.
larynx
Most laryngeal cancers in Europe are due to tobacco smoking,
alcohol drinking and their interaction [46]. The decline in
smoking prevalence in men can largely explain the fall in male
laryngeal cancer mortality rates in the EU since the mid-1980s,
particularly in middle age [47]. Tobacco prevalence also largely
explains the geographic distribution of laryngeal cancer in
Europe, with the highest mortality rates during 2000–2004
(5.5–8.5/100 000) in Belarus, Hungary, Russia, Poland,
Romania, the Baltic countries and Bulgaria. Moreover,
mortality rates have been appreciably declining in the last two
decades, particularly in France and Italy, due to the fall in
alcohol drinking in these countries [16], but also, though more
recently and to a much smaller degree, in Hungary and other
high-mortality areas of central and eastern Europe. Laryngeal
cancer mortality rates have not been declining in Scotland likely
because of the increase in alcohol consumption over recent
decades [16]. Laryngeal cancer mortality rates are very low, and
largely unremarkable in women, though some modest rises
have been observed in Hungary, Poland, Denmark and
Scotland over recent years in women too.
trachea, bronchus and lung
In the EU as a whole, lung cancer mortality has been declining
in men from the overall peak of 53.3/100 000 in the late 1980s
to 44.0/100 000 in the early 2000s (217%, and 210% from
1995–1999 to 2000–2004, only). The fall was even larger in
middle age, from 80.4 to 61.3/100 000 (224%, 212% over the
last 5 years only). In women, in contrast, over the same
calendar period, lung cancer mortality increased from 9.0 to
11.4/100 000 (+27%) at all ages and from 13.9 to 18.5/100 000
(+33%) at age 35–64. Corresponding percent changes were
+17% in middle age and +25% over the last decade alone. Over
the last few years, the annual percent change (APC) for men in
major western European countries were between 22% and
24% and were appreciably negative in most central and eastern
European countries, too. In women, the recent APCs were
variable between 20.7% in England and Wales and +4% in
France, up to +6% in Spain. Over the last few years, falls in
male lung cancer mortality were observed in all European
countries (except Portugal, which had, however, relatively low
rates) including those with the highest mortality rates and the
most unfavourable trends until the late 1990s such as Hungary,
Russia and the Baltic countries. During 2000–2004, the highest
male lung cancer mortality rates were in Hungary (78.9/
100 000) followed by Poland, Croatia, the Czech Republic,
Russia and the Baltic countries with mortality rates between 55
and 68/100 000; the lowest lung cancer mortality rates were in
Sweden (21/100 000) and Portugal (29/100 000). The largest
EU countries (Italy, France, Germany and the UK) had
mortality rates between 35 and 46/100 000. In women, the
highest mortality rates during 2000–2004 were in Scotland and
Hungary (>28/100 000), and the lowest ones (5–6/100 000) in
Portugal and Spain but also in Russia and the Baltic countries.
Lung cancer mortality rates and trends in various countries
essentially reflect the different spread, and the subsequent
decline of cigarette smoking in successive generations of men
and women in various countries [15, 44, 48]. Occupational
agents, including mainly asbestos, were responsible for an
estimated 5%–10% of lung cancers in industrialised countries
[49, 50]. It is likely that the control of asbestos and other
carcinogenic exposures in the workplace has contributed to the
fall in male lung cancer mortality rates over the last decades,
whereas the role of indoor [51] and outdoor [52] air pollution
remains difficult to quantify in Europe.
connective and soft tissue sarcomas
This is a heterogeneous group of neoplasms, showing low
mortality rates and variable trends over time. Thus, over recent
years, their mortality rates have been rising in Italy but
declining in Germany and most other central and northern
European countries. Some of these falls may be due to the
recent control of the acquired immunodeficiency syndrome-
related epidemic of Kaposis sarcoma due to the administration
of highly active antiretroviral therapy [53], but this can account
for a small proportion of the trends only.
skin, including melanoma
Mortality from all skin cancers (including melanoma and
nonmelanomatous skin neoplasms) was moderately, but
steadily, upwards in the EU, particularly in men and in the
elderly, over the last decade. During 2000–2004, overall
mortality rates in the EU reached 2.4/100 000 men and 1.5/
100 000 women. Mortality rates in middle age were stable over
the last decade, confirming that the upward trends are levelling
off in young generations [54]. The recent rises were larger in
eastern Europe (Poland, Romania and Russia), while levelling
off and declines were observed in Austria, Denmark, Germany,
Italy, Spain and Switzerland. During 2000–2004, the highest
mortality rates (>4/100 000 men, >3/100 000 women) were in
Denmark, Norway, Slovenia, Hungary and the Nordic and
Baltic countries; the lowest ones were in Greece, Portugal,
Spain, Bulgaria and Russia. Mortality rates and trends for skin
cancer are influenced by variation in skin cancer diagnosis and
certification across countries and calendar years. There is strong
evidence of a carcinogenic role of ultraviolet radiation in skin
cancer [46, 55, 56]. Intermittent exposure to sunshine appears
original article Annals of Oncology
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to play a more important role than cumulative exposure in
melanoma (but not squamous cell cancers) risk. Changing
patterns of exposure to sunshine over time and in different
generations are related to time trends in skin cancer mortality
[57], whereas phenotype characteristics of various European
populations are strong determinants of geographic variation,
since light colour of hair and eyes and skin complexion are risk
factors for skin cancer, including melanoma [55].
breast
From 1990–1994 to 2000–2004, breast cancer mortality in the
EU declined from 20.8 to 18.1/100 000 (213%) at all ages and
from 40.3 to 33.6/100 000 (217%) at age 35–64 years. An even
larger decline, from 16.7 to 12.6/100 000 (225%), was
registered at age 35– 44 years, whereas the falls were modest
(26%) at age ‡65. During 2000–2004, the range of variation
across Europe was relatively limited, i.e. between 25.9/100 000
in Denmark and 14.5/100 000 in Spain. The largest EU
countries (UK, Germany, France and Italy) had mortality rates
between 18 and 20.5/100 000 and Russia of 17.3/100 000. In the
UK and most other western European countries, mortality rates
have been substantially declining over the last two decades,
whereas they have been stable or upwards in Russia and most
eastern European countries. This has led to a levelling of breast
cancer mortality rates across the continent. Improved
treatment through antiestrogens and chemotherapy had
a major role in the favourable breast cancer mortality trends in
western Europe [58, 59], but a favourable impact of screening
mammography is also likely over recent years [58, 60, 61]. The
decline in the use of menopause hormone replacement therapy
after the publication of the Women’s Health Initiative study
during 2002 [62] has been suggested to have an impact on
breast cancer incidence [63], but the issue remains open to
discussion [64], and its impact on mortality is still undefined.
uterus (cervix and corpus)
In several countries it is not possible to distinguish, on the basis
of death certification, cervical and endometrial cancer, but the
trends in uterine cancer mortality have likely been affected
mostly by the fall in cervical cancer. The long-term decline in
(cervix) uterine cancer mortality has continued over the last
decade (from 1990–1994 and 2000–2004), with a fall from 7.1
to 5.7/100 000 (219%) in overall mortality rates, and from
12.5 to 10.1/100 000 (219%) at age 35–64 years. This is
essentially due to a wider adoption of cervical screening
programmes in western and northern Europe [65]. During
2000–2004, all western European countries had uterine cancer
mortality rates <6/100 000, and most of them between 4 and 5/
100 000. Uterine cancer mortality rates were, however, not
favourable in Russia, Romania, Bulgaria and the Baltic
countries, and were only moderately downwards in the Czech
Republic, Hungary and Poland over the last decades.
Consequently, in those countries, mortality rates during 2000–
2004 (as in the past [66]) were extremely high, i.e. between 9.1/
100 000 in the Czech Republic and 14.7/100 000 in Romania.
This calls for urgent adoption of organised cervical screening
programmes in eastern Europe, too [67, 68]. Data are
inadequate to evaluate trends in mortality from endometrial
cancer, but there is little indication of major changes over time,
unless the increased prevalence of obesity has unfavourably
influenced its incidence [46].
ovary
From 1990–1994 to 2000–2004, in the EU as a whole, ovarian
cancer mortality declined from 6.2 to 5.9/100 000 at all ages
(25%) and from 10.9 to 9.9/100 000 (29%) at age 35–64
years. The falls were larger and started earlier in Austria,
Germany, Switzerland, The Netherlands, the Nordic countries
and the UK, i.e. in countries where oral contraceptives
(OC)—known to have a long-term favourable effect on ovarian
cancer risk [69–71]—had been used earlier and most widely.
Ovarian cancer trends, in contrast, were less or not favourable
in most southern and eastern Europe, where OC had been less
extensively used. During 2000–2004, the highest mortality rates
were in Denmark, Ireland and Lithuania (8–9/100 000) and the
lowest ones in Portugal and Romania (3–4/100 000), and
France and Italy also had relatively low mortality rates. Some of
the recent decline, mostly in young and middle age, may be due
to improved diagnosis and treatment (particularly for germ-cell
tumours [72]) and consequent increased survival [23].
prostate
In the EU as a whole, prostate cancer mortality showed
a modest decline from 1990–1994 to 2000–2004 (from 14.9 to
14.3/100 000, 24% at all ages and from 5.9 to 5.5/100 000,
27% at age 35–64). Both in western Europe [73] and in the
United States [58, 74], peak mortality rates for prostate cancer
were observed in the 1990s, with a levelling off thereafter. Falls
were observed in the last decade in France, Germany and the
UK, whereas prostate cancer mortality rates were still upwards
in Russia, the Baltic countries, Poland and other central and
eastern European countries. Since Bulgaria, Ukraine and Russia
had the lowest prostate cancer mortality rates (<10/100 000, as
compared with 22–23/100 000 in the Nordic countries during
2000–2004), the apparent upward trends in these countries are
likely due, at least in part, to improved diagnosis and
certification of prostate cancer deaths over more recent
calendar years. The recent trends in prostate cancer mortality in
western Europe are consistent with a favourable impact of
advancements in treatment—including hormone therapy
(androgen blockage), wider adoption of radical prostatectomy
in the elderly and radiotherapy for patients with locally
advanced diseases [75–77]—and less likely to the introduction
of prostate-specific antigen test [78, 79].
testis
Testicular cancer mortality has steadily declined in the EU from
1990–1994 to 2000–2004, from 0.47 to 0.35/100 000 (226%) at
all ages and from 0.59 to 0.46/100 000 (222%) at age 35–64.
This follows a favourable trend observed since the 1970s, which
was, however, delayed as compared with that observed in the
United States [80, 81]. The largest declines were in adolescent
and young adults below age 35 [82], but falls were also observed
in subsequent age groups. The declines were observed in most
European countries, major exceptions being Hungary, Latvia
and Romania. Consequently, the highest mortality rates during
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2000–2004 were in those countries, as in Bulgaria, Macedonia
and the Czech Republic (0.6–0.9/100 000), while testicular
cancer mortality rates in most western European countries
ranged between 0.2 and 0.3/100 000. Testicular
cancer—particularly seminomas and teratomas in young
men—is one of the most curable neoplasms if adequate
treatment is adopted. Still, even in more recent years,
substantial differences persisted in mortality from this
neoplasm between western and eastern European countries,
due to inadequate availability of platinum-derived and other
expensive drugs required to treat testicular cancer [80].
Likewise, mortality from testicular cancer substantially declined
in North America but less so in Latin America [81].
Widespread adoption of efficacious therapy is therefore
a priority to avoid unnecessary deaths from testicular cancer
worldwide, and specifically in several areas of central and
eastern Europe.
bladder
Bladder cancer mortality in the EU declined from 1990–1994 to
2000–2004, mostly in men, from 7.2 to 6.1/100 000 (215%) at
all ages and from 5.9 to 4.6/100 000 (223%) at age 35–64,
while the falls in women were around 10%, to reach 1.3/
100 000 at all ages and 1.0/100 000 at age 35–64 during 2000–
2004. Bladder cancer is related to tobacco smoking and
occupational exposure to aromatic amines, particularly in the
past [83]. Not surprisingly, therefore, the falls in men were
larger in western and northern Europe, where the decline in
tobacco consumption among men and the control of
occupational carcinogens were earlier [15, 83]. During 2000–
2004, the highest bladder cancer mortality rates in men were in
Spain, Poland, Latvia and Denmark (8–9/100 000), and lowest
ones (4/100 000) in Sweden, Switzerland and Ireland. In
women, the highest mortality rates were in Denmark and the
UK, and the lowest ones in southern Europe and Romania,
again reflecting the different patterns of tobacco smoking in
various generations of men and women across Europe. The
recent fall in women may, at least in part, be due to improved
control of urinary tract infections, which are another
recognised risk factor for bladder cancer [46], while the role of
diet and other potential urinary tract carcinogens in national
bladder cancer mortality remains undefined [84].
kidney and other urinary organs
Mortality from kidney cancer has increased throughout Europe
until the early 1990s, but has tended to stabilise and decline
thereafter. From 1990–1994 to 2000–2004, the decline was from
4.8 to 4.2/100 000 (212%) in men at all ages and from 6.7 to
5.7/100 000 (215%) at age 35–64. In women, corresponding
falls were from 2.1 to 1.8/100 000 (214%) and from 2.8 to
2.2/100 000 (221%). In men, the highest mortality rates during
2000–2004 were in the Czech Republic (10.5/100 000) and the
Baltic countries (>7/100 000) and the lowest ones (<3/100 000)
in Greece, Portugal, Bulgaria and Romania. Tobacco smoking
is the best recognised risk factor for kidney cancer [85].
Consequently, the reduced prevalence of smoking in most
European countries can explain, at least in part, the recent
favourable trends in men, but they cannot account for female
trends. Other risk factors for kidney cancer are overweight and
hypertension [86]. Trends in overweight and obesity cannot
explain the favourable trends observed in kidney cancer
mortality as, if anything, overweight and obesity have tended to
increase over the last few years in several European countries
[87]. Hypertension has also been related to kidney cancer,
although it remains unclear whether pharmacological control
of hypertension might have had some effect on kidney cancer
mortality [87–89]. The impact of reduced occupational
exposure on kidney cancer risk remains unquantified but is
smaller than for bladder cancer [87].
thyroid
Thyroid cancer is more common in women than in men during
2000–2004. The highest mortality rates in women, around 0.6/
100 000, were in Malta, Iceland, the Baltic countries, the Czech
Republic and Austria, whereas most other European countries
had mortality rates around 0.3/100 000. The geographic pattern
of thyroid cancer mortality was similar in men, though
mortality rates were somewhat lower. Contrary to incidence,
which has been steadily rising [90], thyroid cancer mortality has
declined in the EU from 1990–1994 to 2000–2004. The fall was
from 0.54 to 0.40/100 000 in women (226%) and from 0.40 to
0.33/100 000 in men (217%) and was larger in middle age,
approaching 40% in women and 25% in men. Ionising
radiation, particularly in childhood, is the best established risk
factor for thyroid cancer, together with history of goitre and
other benign thyroid diseases [90]. Nutrition and dietary factors
may also have some role [91]. The main reasons for the decline
in mortality over the last decades, however, are improved
diagnosis and treatment, particularly in younger women [46].
Hodgkin lymphomas
Mortality from Hodgkin lymphomas (HL) continued to decline
across Europe. From 1990–1994 to 2000–2004, in the EU as
a whole, the fall was from 0.82 to 0.49/100 000 (240%) in men
and from 0.48 to 0.31/100 000 (235%) in women. In both
sexes, the falls approached 50% in young and middle age.
Appreciable declines in HL mortality were observed in central
and eastern Europe too, where substantial delays were present
in previous decades [92]. The only country not showing
favourable trend over the last decade was Greece, possibly due
to misclassification with NHL (see below). Thus, during 2000–
2004, the highest HL mortality rates over recent calendar years
were in Greece (1.4/100 000 men, 0.9/100 000 women) and
central and eastern European countries (0.6–.9/100 000 men,
0.4–0.5/100 000 women), while most western and northern
Europe had mortality rates of 0.3–0.4/100 000 for men and 0.2–
0.4/100 000 for women. Trends were downwards also in the
Nordic countries, Germany and the UK, showing already the
lowest mortality rates in the past. Thus, areas of central and
eastern Europe still in more recent years had HL mortality rates
comparable to those observed in western Europe in the early
1990s [92], reflecting a delay in the adoption of efficacious
integrated therapies for this highly curable disease. There is
therefore still a considerable gap in HL mortality across various
areas of Europe, which calls for urgent interventions to control
this largely avoidable cause of death.
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non-Hodgkin lymphomas
NHL was one of the few groups of neoplasms showing upward
trends up to the late 1990s in Europe, as well as in North
America and Japan [93–95]. In the EU as a whole, the peak for
NHL mortality was reached in the late 1990s at 4.3/100 000
men and 2.7/100 000 women. The decline in the subsequent
quinquennium (from 1995–1999 to 2000–2004) was 7% for
both sexes at all ages, to 4.0/100 000 men and 2.5/100 000
women, and >10% at age 35–64. During 2000–2004, the highest
mortality rates (5/100 000 men, 3.5/100 000 women) were in
Finland, The Netherlands, Britain and Ireland, the Nordic
countries and Italy, and the lowest ones (around or below
2/100 000 men and 1.5/100 000 women) were in Greece
(possibly due to substantial misclassification with HL), Russia
and eastern Europe. Over the last few years, trends were variable
across European countries, but they were downwards in larger
ones. The steady rises registered in NHL mortality rates up to the
late 1990s partly or largely reflect real increases in disease
incidence, though their reasons remain largely undefined, and
improved diagnosis and classification of lymphomas and
leukaemias may have played some role too. The recent falls in
mortality are also likely to reflect some improvement in disease
management and treatment, though their impact on national
mortality rates remains unquantified [95].
multiple myeloma
After long-term rises, mortality from MM has stabilised in the
EU over the last few years, around 2.2/100 000 men and 1.5/
100 000 women, while a modest decline (5%) was observed
in middle age. Death certification rates from MM have been
considerably influenced by improvements in diagnosis and
classification. Thus, countries like Sweden and other Nordic
countries or Switzerland [96], where diagnosis and certification
of MM has long been more reliable, showed declines in
mortality in the last decade, particularly in middle age, whereas
mortality rates have been upwards at least up to the late 1990s
in most southern and eastern Europe. Still, during 2000–2004,
the highest MM mortality rates were observed in the Nordic
countries and the lowest ones in eastern and southern Europe,
indicating that there is still scope for diagnostic improvements.
Some of the recent declines may be due to therapeutic
advancements [97–99], which are, however, difficult to quantify
on national mortality.
leukaemias
Mortality from leukaemias continued its long-term favourable
trends, essentially due to persistent therapeutic advancements
[100]. From 1990–1994 to 2000–2004, the overall fall in
leukaemia mortality in the EU was 8% in both sexes (from 5.7
to 5.3/100 000 men, from 3.6 to 3.3/100 000 women). The falls
were larger at younger age, i.e. 15% in young adults, but were
observed up to age 65. The declines were later and smaller in
eastern and southern Europe, and the highest mortality rates
during 2000–2004 (>6/100 000 men, >3.5/100 000 women)
were in Hungary, the Baltic countries, the Czech Republic and
Greece. The lowest ones (<5/100 000 men and <3/100 000
women) were in the Nordic countries, the UK and Switzerland.
As for HL, most eastern European countries had leukaemia
mortality rates comparable to those of western Europe in the
1990s. Although national death certification data do not allow
to distinguish various types of leukaemias, they point to
a relevant delay in the adoption of modern effective treatment
in several areas of the continent and hence underline the
importance and the urgency of the adoption of up-to-date
knowledge on the treatment of leukaemia in southern and,
mostly, in eastern Europe, which may lead to the avoidance of
several hundred deaths per year in the EU as a whole.
all neoplasms
From 1990–1994 to 2000–2004, overall cancer mortality in the
EU declined from 185.2 to 168.0/100 000 (29%) in men and
from 104.8 to 96.9/100 000 (28%) in women. The falls were
larger in middle age, i.e. from 240.8 to 204.2/100 000 (215%)
in men and from 152.3 to 137.0/100 000 (210%) in women.
These falls were of comparable magnitude as those observed
over the last decade in the United States (20.8% per year in
men, 20.4% in women) [33] and in Japan [35]. The falls in the
EU approached 25% in men and 20% in women at age 35–44
years. These particularly favourable trends in the young are of
major importance since they shed light on likely trends in
future generations [101]. Over the last decade, overall cancer
mortality trends were favourable, though to a variable degree,
in all European countries, including Russia, with the sole
exception of Romania. Over the last few years, the APCs in
major western European countries were between 20.5% (in
Spain) and over 22% (in France and Germany), but were
considerably less favourable in women, and in both sexes in
central and eastern Europe.
conclusions
This updated analysis of the mortality from cancer in Europe
showed persistent favourable trends over the last years, whose
major determinants were the decline of lung and other tobacco-
related cancers in men since the early 1990s, together with the
persistent steady falls in gastric cancer, and the recent
appreciable falls in colorectal cancers, particularly in women. In
women, relevant contributions came from the persistent
decline in cervical cancer and—mainly from the more recent
falls—in breast cancer mortality, particularly in northern and
western Europe. Both these declines were related to screening
and early diagnosis, although the fall in breast cancer mortality
is mainly due to improved treatment [58, 102]. Adoption of
standard therapeutic protocols has also played a role in the
reduced mortality from testicular cancer, HL, leukaemias and
other neoplasms amenable to treatment, although the declines
in mortality from these cancers were substantially delayed and
much smaller in eastern European countries [103].
Advancements in integrated treatments have also likely played
a role in colorectal, ovarian and prostatic cancer mortality
trends, among others, though they are difficult to quantify [23].
These advancements notwithstanding, in the early 2000s, there
remains an approximately twofold difference in cancer
mortality—as in incidence [23, 104]—across European
countries. For men, the highest mortality rates during 2000–
2004 were in Hungary (255.2/100 000), the Czech Republic
(215.9/100 000) and Poland (209.8/100 000), and the lowest
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ones in Sweden (125.8/100 000), Finland (130.9/100 000) and
Switzerland (136.9/100 000). For women, the highest mortality
rates were in Denmark (141.0/100 000), Hungary (131.5/
100 000) and Scotland (123.1/100 000), and the lowest ones in
Spain (78.9/100 000), Greece (79.7/100 000) and Portugal
(80.9/100 000), again reflecting the different spread of cigarette
smoking among men and women across various European
countries in the past. Thus, further reduction of tobacco
smoking remains the key priority for cancer control in Europe.
Interventions in alcohol drinking, aspects of nutrition,
including overweight and obesity [105], and more widespread
adoption of screening, early diagnosis and therapeutic
advancements for treatable cancers would contribute to further
reduce European cancer burden in the near future [65].
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